Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
暂无分享,去创建一个
F. Bosch | M. Esteller | E. Musulen | P. Blecua | G. Roué | P. Menéndez | C. de la Torre | M. Ribeiro | J. Santos | J. Bech-Serra | E. Normant | M. Vinyoles | H. Miskin | M. Armengol | D. Reyes-Garau | M. Fernández-Serrano | N. Profitós Pelejà | Alicia Sedo Mor